Research Analysts Issue Forecasts for ARTV FY2025 Earnings

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) – Stock analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for Artiva Biotherapeutics in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer expects that the company will post earnings per share of ($2.72) for the year. The consensus estimate for Artiva Biotherapeutics’ current full-year earnings is ($4.95) per share.

Several other analysts have also recently issued reports on ARTV. HC Wainwright began coverage on shares of Artiva Biotherapeutics in a research report on Monday, December 30th. They set a “buy” rating and a $20.00 target price on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 target price on shares of Artiva Biotherapeutics in a research report on Wednesday, November 13th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $21.00.

Artiva Biotherapeutics Stock Up 8.3 %

Shares of ARTV stock opened at $7.07 on Wednesday. Artiva Biotherapeutics has a 52-week low of $6.38 and a 52-week high of $17.31. The business has a fifty day simple moving average of $10.61.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.24).

Institutional Trading of Artiva Biotherapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. State Street Corp acquired a new stake in Artiva Biotherapeutics during the 3rd quarter worth $1,337,000. Geode Capital Management LLC acquired a new position in shares of Artiva Biotherapeutics in the 3rd quarter valued at $4,774,000. BNP Paribas Financial Markets purchased a new position in Artiva Biotherapeutics during the third quarter worth about $42,000. Barclays PLC acquired a new position in shares of Artiva Biotherapeutics in the 3rd quarter worth approximately $304,000. Finally, Franklin Resources Inc. acquired a new position in Artiva Biotherapeutics during the third quarter worth $7,435,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.